Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes : A randomized double-blind placebo-controlled trial. / Johansen, Nicklas J.; Dejgaard, Thomas F.; Lund, Asger; Schluentz, Camilla; Larsen, Emil L.; Poulsen, Henrik E.; Goetze, Jens P.; Møller, Holger J.; Vilsbøll, Tina; Andersen, Henrik U.; Knop, Filip K.

I: Diabetes, Obesity and Metabolism, Bind 22, Nr. 9, 2020, s. 1639-1647.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Johansen, NJ, Dejgaard, TF, Lund, A, Schluentz, C, Larsen, EL, Poulsen, HE, Goetze, JP, Møller, HJ, Vilsbøll, T, Andersen, HU & Knop, FK 2020, 'Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial', Diabetes, Obesity and Metabolism, bind 22, nr. 9, s. 1639-1647. https://doi.org/10.1111/dom.14078

APA

Johansen, N. J., Dejgaard, T. F., Lund, A., Schluentz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2020). Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. Diabetes, Obesity and Metabolism, 22(9), 1639-1647. https://doi.org/10.1111/dom.14078

Vancouver

Johansen NJ, Dejgaard TF, Lund A, Schluentz C, Larsen EL, Poulsen HE o.a. Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. Diabetes, Obesity and Metabolism. 2020;22(9):1639-1647. https://doi.org/10.1111/dom.14078

Author

Johansen, Nicklas J. ; Dejgaard, Thomas F. ; Lund, Asger ; Schluentz, Camilla ; Larsen, Emil L. ; Poulsen, Henrik E. ; Goetze, Jens P. ; Møller, Holger J. ; Vilsbøll, Tina ; Andersen, Henrik U. ; Knop, Filip K. / Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes : A randomized double-blind placebo-controlled trial. I: Diabetes, Obesity and Metabolism. 2020 ; Bind 22, Nr. 9. s. 1639-1647.

Bibtex

@article{9c64ea40f2eb452e8fc0a94fd4f36a81,
title = "Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial",
abstract = "Aims To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods In a randomized, double-blind, parallel-group trial, 108 individuals with type 1 diabetes aged >= 18 years on multiple daily injection therapy with a body mass index >22.0 kg/m(2)and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 mu g exenatide (Byetta (R)) or placebo three times daily over 26 weeks as add-on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population. The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported. Results Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6;P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4;P= 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-alpha; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2 '-deoxyguanosine (DNA oxidation marker). Conclusions Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.",
author = "Johansen, {Nicklas J.} and Dejgaard, {Thomas F.} and Asger Lund and Camilla Schluentz and Larsen, {Emil L.} and Poulsen, {Henrik E.} and Goetze, {Jens P.} and M{\o}ller, {Holger J.} and Tina Vilsb{\o}ll and Andersen, {Henrik U.} and Knop, {Filip K.}",
year = "2020",
doi = "10.1111/dom.14078",
language = "English",
volume = "22",
pages = "1639--1647",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes

T2 - A randomized double-blind placebo-controlled trial

AU - Johansen, Nicklas J.

AU - Dejgaard, Thomas F.

AU - Lund, Asger

AU - Schluentz, Camilla

AU - Larsen, Emil L.

AU - Poulsen, Henrik E.

AU - Goetze, Jens P.

AU - Møller, Holger J.

AU - Vilsbøll, Tina

AU - Andersen, Henrik U.

AU - Knop, Filip K.

PY - 2020

Y1 - 2020

N2 - Aims To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods In a randomized, double-blind, parallel-group trial, 108 individuals with type 1 diabetes aged >= 18 years on multiple daily injection therapy with a body mass index >22.0 kg/m(2)and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 mu g exenatide (Byetta (R)) or placebo three times daily over 26 weeks as add-on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population. The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported. Results Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6;P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4;P= 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-alpha; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2 '-deoxyguanosine (DNA oxidation marker). Conclusions Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.

AB - Aims To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods In a randomized, double-blind, parallel-group trial, 108 individuals with type 1 diabetes aged >= 18 years on multiple daily injection therapy with a body mass index >22.0 kg/m(2)and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 mu g exenatide (Byetta (R)) or placebo three times daily over 26 weeks as add-on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population. The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported. Results Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6;P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4;P= 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-alpha; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2 '-deoxyguanosine (DNA oxidation marker). Conclusions Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.

U2 - 10.1111/dom.14078

DO - 10.1111/dom.14078

M3 - Journal article

C2 - 32543021

VL - 22

SP - 1639

EP - 1647

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -

ID: 244372048